S
SEngine Precision Medicine
SEngine Precision Medicine has engineered an innovative approach to identify and develop the next generation of cancer targeted drugs
About SEngine Precision Medicine
SEngine Precision Medicine is a biotechnology company that specializes in personalized cancer treatment. The company operates in the healthcare sector, specifically focusing on oncology. SEngine's core service is the PARIS Test, which uses high throughput technology to test over 200 cancer drugs against a patient's unique tumor organoid outside the body. This approach helps identify the most effective and least toxic treatment options, surpassing the capabilities of traditional DNA sequencing. The company serves patients, oncologists, research partners, and pharmaceutical companies. SEngine's business model involves providing actionable reports directly to oncologists, which helps in making informed treatment decisions. The company generates revenue through the sale of its PARIS Test and partnerships with pharmaceutical companies for drug development. SEngine's proprietary platform also leverages aggregated, anonymized test results to aid in the development of new cancer-fighting drugs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 36.1/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Testing, Oncology, Drug Development, Core AI, Precision Medicine, Hard Tech, AI Applications, medical testing
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2022 | $10M | $40M | Alethea Fulcrum Fund · Vincere Capital Biotech · Bangarang Group | ↗ |
| SERIES A✓Equity / VC | Oct 2019 | $5.1M | $20M | Undisclosed | — |
Growth signals
Latest recorded traffic for SEngine Precision Medicine is 750 monthly website visits, down 68.8% over the last three months. SEngine Precision Medicine's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A3 investors entered at this stage
- AFAlethea Fulcrum Fund
- VBVincere Capital Biotech
- BGBangarang Group
Other known investors1 additional known investor
WRF Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about SEngine Precision Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SEngine Precision Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.